. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Pediatr Blood Cancer. 2020 Nov 27;68(3):e28832. doi: 10.1002/pbc.28832

Table 3.

Five-year EFS and OS estimate with 95% CI by protocol

		5-year EFS (95% CI)	5-year OS (95% CI)
Cohort RMS2005		49% (38.80%–59.25%)	51% (40.90%–60.87%)
Cohort ARST0531		44% (29.96%–58.14%)	53.6% (39.61%–67.69%)
FOXO1 fusion negative (cohorts combined)		63% (44.61%–81.03%)	69% (51.71%–86.26%)
FOXO1 fusion positive (cohorts combined)		47.6% (37.21%–58.06%)	52.7% (42.62%–62.93%)
FOXO1 fusion status for RMS2005	Negative	73 % (53.00%–92.76%)	76% (57.22%–94.89%)
FOXO1 fusion status for RMS2005	Positive	49.3 % (35.80%–62.79%)	51.6% (38.57%–64.71%)
FOXO1 fusion status for ARST0531	Negative	43.8% (6.62%–80.88%)	56.2% (19.79%–92.71%)
FOXO1 fusion status for ARST0531	Positive	45% (28.76%–61.53%)	53.7% (37.74%–69.79%)
Primary site (cohorts combined)	Extremities	38% (23.77%–52.22%)	50% (35.87%–64.17%)
	Parameningeal	46.5% (30.79%–62.22%)	47.4% (31.51%–63.27%)
	All other sites	55.5% (42.51%–68.58%)	57% (44.19%–69.69%)